Clinical Research Directory
Browse clinical research sites, groups, and studies.
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
Sponsor: Mayo Clinic
Summary
The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically relevant entity with a risk of progression to fulminant myocarditis.
Official title: Positron Emission Tomography for the Detection of Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis (PET-SIM): A Prospective, Single Center, Single Arm, Open Label Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2024-10-11
Completion Date
2027-04-30
Last Updated
2025-10-15
Healthy Volunteers
No
Conditions
Interventions
Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
Receive 18F-FDG PET/CT
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States